Biocon [BIOCON] vs Glenmark [GLENMARK] Detailed Stock Comparison
Biocon
NSE
Loading...
Glenmark
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biocon wins in 9 metrics, Glenmark wins in 11 metrics, with 0 ties. Glenmark appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biocon | Glenmark | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 113.56 | 77.02 | Glenmark |
| Price-to-Book Ratio | 2.01 | 6.75 | Biocon |
| Debt-to-Equity Ratio | 66.26 | 27.94 | Glenmark |
| PEG Ratio | -1.19 | -0.89 | Biocon |
| EV/EBITDA | 19.66 | 23.76 | Biocon |
| Profit Margin (TTM) | 2.44% | 5.60% | Glenmark |
| Operating Margin (TTM) | 7.46% | 13.80% | Glenmark |
| EBITDA Margin (TTM) | 7.46% | 13.80% | Glenmark |
| Return on Equity | 3.66% | 11.83% | Glenmark |
| Return on Assets (TTM) | 1.72% | 6.52% | Glenmark |
| Free Cash Flow (TTM) | $17.18B | $-15.77B | Biocon |
| Dividend Yield | 0.26% | 0.15% | Biocon |
| 1-Year Return | -2.68% | 20.51% | Glenmark |
| Price-to-Sales Ratio (TTM) | 3.08 | 4.31 | Biocon |
| Enterprise Value | $634.39B | $587.04B | Biocon |
| EV/Revenue Ratio | 4.02 | 4.36 | Biocon |
| Gross Profit Margin (TTM) | 64.06% | 66.80% | Glenmark |
| Revenue per Share (TTM) | $131 | $477 | Glenmark |
| Earnings per Share (Diluted) | $3.20 | $26.67 | Glenmark |
| Beta (Stock Volatility) | 0.23 | 0.30 | Biocon |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biocon vs Glenmark Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biocon | 0.12% | 4.41% | -2.32% | 10.01% | 11.96% | -1.38% |
| Glenmark | -0.03% | 6.65% | -0.03% | 29.47% | 47.83% | 27.09% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biocon | -2.68% | 20.37% | -16.02% | 399.59% | 530.99% | 847.88% |
| Glenmark | 20.51% | 427.55% | 322.94% | 104.65% | 619.08% | 2,814.22% |
Performance & Financial Health Analysis: Biocon vs Glenmark
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Market Information | ||
| Market Cap | ₹485.52B | ₹581.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,035,256 | 638,971 |
| 90 Day Avg. Volume | 3,068,471 | 794,957 |
| Last Close | ₹364.15 | ₹2,051.30 |
| 52 Week Range | ₹291.00 - ₹406.00 | ₹1,275.50 - ₹2,284.80 |
| % from 52W High | -10.31% | -10.22% |
| All-Time High | ₹487.75 (Dec 21, 2020) | ₹2,284.80 (Jul 11, 2025) |
| % from All-Time High | -25.34% | -10.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.01% |
| Quarterly Earnings Growth | -0.95% | -0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.06% |
| Operating Margin (TTM) | 0.07% | 0.14% |
| Return on Equity (TTM) | 0.04% | 0.12% |
| Debt to Equity (MRQ) | 66.26 | 27.94 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹180.66 | ₹304.50 |
| Cash per Share (MRQ) | ₹38.10 | ₹60.39 |
| Operating Cash Flow (TTM) | ₹17.78B | ₹2.11B |
| Levered Free Cash Flow (TTM) | ₹10.13B | ₹10.47B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.26% | 0.15% |
| Last 12-Month Dividend | ₹1.00 | ₹2.50 |
Valuation & Enterprise Metrics Analysis: Biocon vs Glenmark
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 113.56 | 77.02 |
| Forward P/E | 36.63 | 48.36 |
| PEG Ratio | -1.19 | -0.89 |
| Price to Sales (TTM) | 3.08 | 4.31 |
| Price to Book (MRQ) | 2.01 | 6.75 |
| Market Capitalization | ||
| Market Capitalization | ₹485.52B | ₹581.88B |
| Enterprise Value | ₹634.39B | ₹587.04B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.02 | 4.36 |
| Enterprise to EBITDA | 19.66 | 23.76 |
| Risk & Other Metrics | ||
| Beta | 0.23 | 0.30 |
| Book Value per Share (MRQ) | ₹180.66 | ₹304.50 |
Financial Statements Comparison: Biocon vs Glenmark
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIOCON | GLENMARK |
|---|---|---|
| Revenue/Sales | ₹39.10B | ₹32.20B |
| Cost of Goods Sold | ₹14.05B | ₹10.89B |
| Gross Profit | ₹25.05B | ₹21.31B |
| Research & Development | ₹-346.00M | N/A |
| Operating Income (EBIT) | ₹2.94B | ₹4.36B |
| EBITDA | ₹8.29B | ₹2.00B |
| Pre-Tax Income | ₹969.00M | ₹79.74M |
| Income Tax | ₹77.00M | ₹35.90M |
| Net Income (Profit) | ₹892.00M | ₹43.84M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIOCON | GLENMARK |
|---|---|---|
| Cash & Equivalents | ₹32.27B | ₹16.76B |
| Total Current Assets | ₹162.86B | ₹92.95B |
| Total Current Liabilities | ₹143.34B | ₹59.67B |
| Long-Term Debt | ₹129.45B | ₹6.99B |
| Total Shareholders Equity | ₹277.13B | ₹88.49B |
| Retained Earnings | ₹189.59B | N/A |
| Property, Plant & Equipment | ₹4.32B | ₹33.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIOCON | GLENMARK |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,035,256 | 638,971 |
| Average Daily Volume (90 Day) | 3,068,471 | 794,957 |
| Shares Outstanding | 1.20B | 282.19M |
| Float Shares | 523.92M | 142.34M |
| % Held by Insiders | 0.56% | 0.51% |
| % Held by Institutions | 0.24% | 0.29% |
Dividend Analysis & Yield Comparison: Biocon vs Glenmark
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹2.50 |
| Last 12-Month Dividend Yield | 0.26% | 0.15% |
| 3-Year Avg Annual Dividend | ₹1.33 | ₹2.50 |
| 3-Year Avg Dividend Yield | 0.36% | 0.38% |
| 3-Year Total Dividends | ₹4.00 | ₹7.50 |
| Ex-Dividend Date | Jul 04, 2025 | Sep 13, 2024 |